PSMA SPECT/CT with 99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Nuclear Medicine"
DOI: 10.1007/s12149-019-01400-6
Abstract: The in vivo expression of the prostate-specific membrane antigen (PSMA) can be investigated using the SPECT-suitable tracer 99mTc-MIP-1404. We investigated the performance of 99mTc-MIP-1404 PSMA SPECT/CT in the detection of PSMA-positive tumor lesions in patients… read more here.
Keywords: mip 1404; 99mtc mip; psma spect; psma positive ... See more keywords
The 99mTc-MIP-1404 PSMA Uptake in the Isolated Paratracheal Lymph Node From the Prostate Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Nuclear Medicine"
DOI: 10.1097/rlu.0000000000004384
Abstract: Abstract The oncologist consulted a 56-year-old man after receiving prostate-specific antigen screening results. Prostate-specific antigen level during the screen time was 33 ng/mL. As a result, poorly differentiated prostate adenocarcinoma with a Gleason score of… read more here.
Keywords: 99mtc mip; prostate; mip 1404; 1404 psma ... See more keywords
Eligibility for 177Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of 68Ga-PSMA-11 and 99mTc-MIP-1404 in Metastatic Castration-Resistant Prostate Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Nuclear Medicine"
DOI: 10.2967/jnumed.122.264296
Abstract: Visual Abstract 177Lu-prostate-specific membrane antigen-617 (177Lu-PSMA-617) is an effective therapy for metastatic castration-resistant prostate cancer (mCRPC), with evidence of improved survival over standard care. The VISION trial inclusion criteria required a metastatic lesion-to-liver ratio of… read more here.
Keywords: 99mtc mip; prostate; mip 1404; lesion ... See more keywords